U.S., March 29 -- ClinicalTrials.gov registry received information related to the study (NCT06900738) titled 'A Study to Evaluate Non-invasive Measurements of the Inflammatory Status in Patients with IBD' on March 14.
Brief Summary: Patients with IBD, including both Crohn's disease and ulcerative colitis, require accurate monitoring of intestinal inflammation for optimal follow-up and treatment. Traditional markers like C-reactive protein (CRP) and faecal calprotectin are useful but are either invasive or disliked by patients and a proper continuous monitoring is not feasible with fragmented biomarker information.
The NimBio technology provides support for the clinicians who are managing IBD patients' care based on a wearable technology t...